Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GENFIT    GNFT   FR0004163111

GENFIT

(GNFT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
3.35(c) 3.248(c) 3.194(c) 3.08(c) 3.122 Last
392 518 456 276 931 089 296 160 264 640 Volume
-4.56% -3.04% -1.66% -3.57% +1.36% Change
More quotes
Financials
Sales 2020 7,11 M 8,30 M 8,30 M
Net income 2020 -72,8 M -85,0 M -85,0 M
Net cash position 2020 80,2 M 93,6 M 93,6 M
P/E ratio 2020 -3,18x
Yield 2020 -
Sales 2021 6,46 M 7,54 M 7,54 M
Net income 2021 -60,9 M -71,1 M -71,1 M
Net cash position 2021 53,6 M 62,6 M 62,6 M
P/E ratio 2021 -1,69x
Yield 2021 -
Capitalization 120 M 139 M 139 M
EV / Sales 2020 5,53x
EV / Sales 2021 10,2x
Nbr of Employees 203
Free-Float 93,4%
More Financials
Company
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich... 
More about the company
Notations Surperformance© of GENFIT
Trading Rating : Investor Rating :
More Ratings
All news about GENFIT
10/01GENFIT : 2020 GENFIT Half year business and financial report
PU
09/30GENFIT : First Half-Year 2020 Financial Report and New Corporate Strategy
AQ
09/30GENFIT : First Half-Year 2020 Financial Report and New Corporate Strategy
GL
09/30GENFIT : First Half-Year 2020 Financial Report and New Corporate Strategy
AQ
09/30GENFIT : First Half-Year 2020 Financial Report and New Corporate Strategy
GL
09/30GENFIT : Half-year results
CO
09/29GENFIT : and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnosti..
AQ
09/28GENFIT : and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnosti..
AQ
09/28GENFIT : and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnosti..
AQ
09/28GENFIT : and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnosti..
GL
09/28GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnost..
GL
09/24GENFIT : Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluatin..
AQ
09/24GENFIT : Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluatin..
AQ
09/24GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluati..
GL
09/24GENFIT : Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluatin..
GL
More news
News in other languages on GENFIT
10/20GENFIT : plus forte baisse du SBF 120 à la mi-séance du mardi 20 octobre 2020
10/20GENFIT : plus forte baisse du SRD à la mi-séance du mardi 20 octobre 2020
10/15AVIS D'ANALYSTES DU JOUR : Adidas, Air Liquide, ASML, EasyJet, Neoen, Sika, Vest..
10/12GENFIT : plus forte baisse du SBF 120 à la clôture du lundi 12 octobre 2020
10/05GENFIT : plus forte baisse du SBF 120 à la mi-séance du lundi 5 octobre 2020 -
More news
Chart GENFIT
Duration : Period :
GENFIT Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENFIT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 8,00 €
Last Close Price 3,08 €
Spread / Highest target 257%
Spread / Average Target 160%
Spread / Lowest Target 62,3%
EPS Revisions
Managers
NameTitle
Pascal Prigent CEO & EVP-Marketing & Development
Jean-FranÁois Mouney Chairman
Dean W. Hum Chief Operating Officer
Nathalie Huitorel EVP, Chief Financial & Administrative Officer
Carol L. Addy Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENFIT-82.55%139
LONZA GROUP AG56.63%44 852
SEAGEN INC.68.34%33 467
CELLTRION, INC.39.78%29 849
IQVIA HOLDINGS INC.0.09%29 650
MODERNA, INC.264.42%28 126